Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Overview

[Pantothenate Kinase-Associated Neurodegeneration (PKAN)](/diseases/pantothenate-kinase-associated-neurodegeneration), formerly known as Hallervorden-Spatz syndrome, is a rare autosomal recessive neurodegenerative disorder and the most common form of [neurodegeneration with brain iron accumulation (NBIA)](/diseases/nbia-neurodegeneration-brain-iron-accumulation). PKAN is caused by mutations in the [PANK2](/genes/pank2) gene, which encodes the mitochondrial enzyme pantothenate kinase 2, the rate-limiting enzyme in coenzyme A biosynthesis. The disease is characterized by progressive [dystonia](/symptoms/[dystonia](/symptoms/dystonia)), [dysarthria](/symptoms/dysarthria), [rigidity](/symptoms/rigidity), and pigmentary retinal degeneration, with pathological iron accumulation in the [globus pallidus(/brain-regions/globus-pallidus(/brain-regions/globus-pallidus) and substantia nigra(/brain-regions/substantia-nigra(/brain-regions/substantia-nigra)). [@acylcarnitine]

Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Overview

[Pantothenate Kinase-Associated Neurodegeneration (PKAN)](/diseases/pantothenate-kinase-associated-neurodegeneration), formerly known as Hallervorden-Spatz syndrome, is a rare autosomal recessive neurodegenerative disorder and the most common form of [neurodegeneration with brain iron accumulation (NBIA)](/diseases/nbia-neurodegeneration-brain-iron-accumulation). PKAN is caused by mutations in the [PANK2](/genes/pank2) gene, which encodes the mitochondrial enzyme pantothenate kinase 2, the rate-limiting enzyme in coenzyme A biosynthesis. The disease is characterized by progressive [dystonia](/symptoms/[dystonia](/symptoms/dystonia)), [dysarthria](/symptoms/dysarthria), [rigidity](/symptoms/rigidity), and pigmentary retinal degeneration, with pathological iron accumulation in the [globus pallidus(/brain-regions/globus-pallidus(/brain-regions/globus-pallidus) and substantia nigra(/brain-regions/substantia-nigra(/brain-regions/substantia-nigra)). [@acylcarnitine]

PKAN has an estimated incidence of 1-3 per million population and accounts for approximately 35-50% of all NBIA cases. The disease presents in two main forms: classic PKAN with early childhood onset (before age 6) and rapid progression, and atypical PKAN with later onset (after age 10) and slower progression. The distinctive "eye of the tiger" sign on brain MRI -- a hyperintense center surrounded by a hypointense rim in the [globus pallidus](/brain-regions/globus-pallidus) on T2-weighted imaging -- is highly characteristic and serves as an important diagnostic marker. [@neuroacanthocytosis]

The disease was originally named Hallervorden-Spatz syndrome after Julius Hallervorden and Hugo Spatz, who first described it in 1922. [The eponymous name was later abandoned due to the documented involvement of both physicians in Nazi-era euthanasia programs and unethical brain research, and the disorder was renamed PKAN following identification of the causative gene in 2001](https://en.wikipedia.org/wiki/Pantothenate_kinase-associated_neurodegeneration). [@pantothenate]

Genetics and Molecular Basis

The PANK2 Gene

The PANK2 gene is located on chromosome 20p13 and encodes pantothenate kinase 2, the mitochondrial isoform of pantothenate kinase. This enzyme catalyzes the first and rate-limiting step of coenzyme A biosynthesis: the phosphorylation of pantothenate (vitamin B5) to 4'-phosphopantothenate . [@targeting]

The PANK2 gene product is the only pantothenate kinase isoform targeted to mitochondria, where [coenzyme A](/proteins/coenzyme-a) is essential for the tricarboxylic acid (TCA) cycle, [fatty acid oxidation](/mechanisms/fatty-acid-oxidation-neurodegeneration), and numerous other metabolic reactions. Between 4% and 9% of all cellular metabolic activities rely on [coenzyme A](/proteins/coenzyme-a) as a cofactor .

Mutation Spectrum

Over 150 pathogenic PANK2 variants have been identified:

• Null (loss-of-function) mutations: Homozygous or compound heterozygous null alleles (frameshifts, nonsense, splice-site mutations) cause complete loss of PANK2 activity and are associated with the classic, severe form of PKAN .
• Missense mutations: Point mutations that result in amino acid substitutions with residual enzyme activity are more commonly associated with atypical PKAN and later onset.
• Common variants: The c.1561G>A (p.Gly521Arg) and c.1583C>T (p.Thr528Met) mutations are among the most frequently identified variants in European populations.
• Genotype-phenotype correlations: Disease severity generally correlates with the degree of residual PANK2 enzyme activity. Patients with two null alleles typically exhibit earlier onset and more rapid decline .

Inheritance

PKAN follows autosomal recessive inheritance. Carrier parents have a 25% chance of having an affected child per pregnancy. Carrier testing and prenatal diagnosis are available for families with known mutations.

Pathophysiology

Coenzyme A Deficiency

The primary biochemical defect in PKAN is impaired [coenzyme A](/proteins/coenzyme-a) biosynthesis in mitochondria:

Iron Accumulation

The hallmark neuropathological feature of PKAN is iron deposition in the [globus pallidus](/brain-regions/globus-pallidus):

• Selective vulnerability: The [globus pallidus](/brain-regions/globus-pallidus) and [substantia nigra](/brain-regions/substantia-nigra) are particularly affected, likely because these regions have the highest baseline iron concentrations and are metabolically active.
• Iron-mediated toxicity: Excess iron catalyzes the generation of hydroxyl radicals through the Fenton reaction, causing oxidative damage to lipids, proteins, and DNA .
• [ferroptosis](/mechanisms/ferroptosis): Recent research has implicated [ferroptosis](/mechanisms/ferroptosis), an iron-dependent form of regulated cell death, in PKAN pathogenesis. Serum metabolomics studies in PKAN patients have revealed [ferroptosis](/mechanisms/ferroptosis)-related biomarker signatures .
• Neuroaxonal dystrophy: Iron deposits are associated with swollen axons (spheroids) and [neuroaxonal dystrophy](/mechanisms/neuroaxonal-dystrophy), contributing to progressive neuronal dysfunction.

Mitochondrial Dysfunction

PANK2 is a mitochondrial enzyme, and its deficiency has direct consequences for mitochondrial function:

• Impaired mitochondrial [coenzyme A](/proteins/coenzyme-a) synthesis reduces [mitochondrial dynamics](/mechanisms/mitochondrial-dysfunction) and respiratory chain efficiency.
• Decreased beta-oxidation leads to lipid accumulation and altered membrane composition.
• Mitochondrial [oxidative stress](/mechanisms/oxidative-stress) further damages the organelle, creating a degenerative feedback loop.

Clinical Features

Classic PKAN

Classic PKAN accounts for approximately 75% of cases and presents with the following features:

• Age of onset: Typically before age 6, with most children presenting between ages 3-4.
• Gait disturbance: Usually the first symptom, with progressive difficulty walking due to [dystonia](/symptoms/dystonia) and rigidity.
• Progressive [dystonia](/symptoms/dystonia): Generalized [dystonia](/symptoms/dystonia) is the hallmark, often beginning in the legs and spreading to involve the trunk, arms, and cranial musculature .
• Oromandibular [dystonia](/symptoms/dystonia): Dystonia of the jaw, face, and tongue leads to dysarthria, feeding difficulties, and drooling.
• Corticospinal tract signs: Spasticity, hyperreflexia, and extensor plantar responses.
• Pigmentary retinopathy: Present in approximately two-thirds of classic PKAN patients; may be detected before neurological symptoms.
• Cognitive decline: Progressive intellectual deterioration, though often less prominent than motor disability.
• Disease course: Rapid progression, with most patients losing the ability to walk within 10-15 years of onset.

Atypical PKAN

Atypical PKAN accounts for approximately 25% of cases:

• Age of onset: After age 10, typically in the teens to early twenties .
• Speech defects: Often the presenting symptom; progressive dysarthria and palilalia.
• Psychiatric symptoms: Depression, anxiety, emotional lability, personality changes, and obsessive-compulsive behaviors may precede motor symptoms by years.
• Movement disorder: Dystonia is present but may be more focal; parkinsonism features (bradykinesia, rigidity) may predominate.
• Cognitive function: May be relatively preserved early, with slower decline than in classic PKAN.
• Pigmentary retinopathy: Less common than in classic PKAN.
• Disease course: Slower progression; patients may retain ambulation for 15-40 years after onset.

Additional Features

• Acanthocytosis: Abnormally shaped red blood cells (acanthocytes) are found in some PKAN patients.
• Seizures: Uncommon but may occur in advanced disease.
• Autonomic dysfunction: Bladder dysfunction, constipation.
• Skeletal deformities: Scoliosis, pes equinovarus secondary to chronic [dystonia](/symptoms/dystonia).

Diagnosis

Neuroimaging

• Brain MRI -- "Eye of the tiger" sign: The pathognomonic finding on T2-weighted MRI is a bilateral symmetric pattern in the [globus pallidus](/brain-regions/globus-pallidus) consisting of a central hyperintense signal (reflecting gliosis and neuronal loss) surrounded by a rim of hypointensity (reflecting iron deposition). This sign is present in virtually all classic PKAN patients .
• T2*/SWI: More sensitive for detecting iron deposition; shows marked hypointensity in the [globus pallidus](/brain-regions/globus-pallidus) and [substantia nigra](/brain-regions/substantia-nigra).
• Early MRI: In very early disease, the full "eye of the tiger" pattern may not yet be present.

Genetic Testing

• PANK2 sequencing: Definitive diagnosis requires identification of biallelic pathogenic variants in PANK2. Sequencing detects approximately 98% of mutations in clinically diagnosed patients .
• NBIA gene panels: Multigene panels testing PANK2 alongside other NBIA genes (PLA2G6, C19orf12, WDR45, FA2H, COASY, FTL, CP) are available.

Ophthalmological Examination

• Electroretinography (ERG): May detect subclinical retinal dysfunction.
• Fundoscopy: May reveal bone-spicule pigmentation characteristic of pigmentary retinopathy.

Laboratory Tests

• Complete blood count with peripheral smear: To detect acanthocytosis.
• Serum ferritin and iron studies: Typically normal (brain iron accumulation is not reflected in peripheral blood).

Treatment and Management

Current Treatment

There is no approved disease-modifying therapy for PKAN. Management is symptomatic and supportive:

Dystonia Management

• Oral medications: Baclofen, trihexyphenidyl, [benzodiazepines](/therapeutics/benzodiazepines-neurodegeneration), and [Tizanidine](/therapeutics/tizanidine-neurodegeneration).
• Botulinum toxin injections: For focal [dystonia](/symptoms/dystonia), particularly oromandibular and cervical [dystonia](/symptoms/dystonia).
• Intrathecal [Baclofen](/therapeutics/baclofen-neurodegeneration): Pump-delivered [Baclofen](/therapeutics/baclofen-neurodegeneration) for severe generalized [dystonia](/symptoms/dystonia).
• [deep brain stimulation](/treatments/[deep brain stimulation](/therapeutics/deep-brain-stimulation)): Bilateral GPi-DBS has shown benefit in some patients. Asymmetric bilateral DBS has been reported as a promising approach in atypical cases .

Supportive Care

• Physical and occupational therapy: To maintain mobility and prevent contractures.
• Speech therapy: For dysarthria and swallowing difficulties.
• Nutritional support: Gastrostomy tube when dysphagia becomes severe.
• Orthopedic interventions: Management of skeletal deformities.
• Visual care: Monitoring pigmentary retinopathy.

Emerging Therapies

[coenzyme A](/proteins/coenzyme-a) Pathway Supplementation

• Pantothenate (vitamin B5): High-dose supplementation investigated as substrate-enhancement strategy.
• Pantethine: A [coenzyme A](/proteins/coenzyme-a) precursor that bypasses the PANK2-catalyzed step.
• [coenzyme A](/proteins/coenzyme-a)-Z (fosmetpantotenate): Modified pantetheine derivative; clinical trials showed safety but did not meet primary efficacy endpoints.
• Multitarget supplements: Pantothenate, pantethine, omega-3, and vitamin E combination showed iron reduction in cellular models .

Iron Chelation

• Deferiprone: Oral iron chelator that crosses the blood-brain-barrier. Some evidence of reduced brain iron on MRI, though clinical benefit has been modest.

Gene Therapy

• [AAV gene therapy](/mechanisms/aav-gene-therapy-vectors-neurodegeneration)-mediated PANK2 gene delivery: Preclinical studies demonstrate feasibility; clinical translation is anticipated.

Prognosis

• Classic PKAN: Progressive course. Most patients become wheelchair-dependent within 10-15 years of onset. Life expectancy is reduced, with death typically in the second to third decade .
• Atypical PKAN: Slower progression with variable outcomes. Some patients retain function for decades.
• Both forms are progressive without remission. Quality of life is significantly impacted by [dystonia](/symptoms/dystonia), speech loss, and feeding difficulties.

See Also

• [deep brain stimulation](/treatments/[deep brain stimulation](/therapeutics/deep-brain-stimulation))

Background

The study of Pantothenate Kinase Associated Neurodegeneration (Pkan) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer](/diseases/alzheimers-disease)'s Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Overexpression of the crp gene promotes biofilm formation and increases antibiotic resistance in bovine-derived Klebsiella pneumoniae.](https://pubmed.ncbi.nlm.nih.gov/41668882/) (2026) - Frontiers in microbiology
• [The acylcarnitine profile in patients with PKAN may mimic CPT1 deficiency.](https://pubmed.ncbi.nlm.nih.gov/41475178/) (2026 Jan) - Molecular genetics and metabolism
• [Neuroacanthocytosis.](https://pubmed.ncbi.nlm.nih.gov/32809602/) (2026 Jan) -
• [Pantothenate Kinase-Associated Neurodegeneration (PKAN).](https://pubmed.ncbi.nlm.nih.gov/28613462/) (2026 Jan) -
• [Targeting pantothenate kinases in human diseases: Biochemistry and pharmacotherapy.](https://pubmed.ncbi.nlm.nih.gov/40754168/) (2025 Dec) - Biochemical pharmacology

Visual Summary

Key Pathway Steps:

Visual Summary

References